Medical Oncology

, Volume 28, Supplement 1, pp 570–576

Short-term outcomes of cetuximab combined with standard chemotherapy as first line setting for Chinese patients with non-small cell lung cancer: a report of 12 cases

  • Liang-Ping Xia
  • Hui-Juan Qiu
  • Xu-Xian Chen
  • Pi-Li Hu
  • Gui-Fang Guo
  • Fang Wang
  • Fei-Fei Zhou
  • Wen-Zhuo He
  • Bei Zhang
  • Li Zhang
Original Paper

DOI: 10.1007/s12032-010-9709-7

Cite this article as:
Xia, LP., Qiu, HJ., Chen, XX. et al. Med Oncol (2011) 28: 570. doi:10.1007/s12032-010-9709-7

Abstract

Cetuximab combined with chemotherapy has been used to treat Non-small cell lung cancer (NSCLC) in recent years, however, the data from China was rare. This study was to summarize our experiences in treating NSCLC patients with cetuximab in the first line setting. From October 1st 2006 to Jun 30th 2010, twelve NSCLC patients were treated with cetuximab combined standard chemotherapy as first line setting in Sun Yat-sen University Cancer Center entered the study and the short-term efficacy and safety were analyzed. A total of 132 cycles of cetuximab treatment, with a median of nine cycles in the whole group were administered. The ORR was 41.7% (5/12), DCR was 83.3% (10/12), median TTP was 5.5 months (2–23), and median OS was 9 months (2–48) in the whole group. There were 75% (9/12) patients occurred acne-like rash within first 3 weeks, their ORR was 55.6% (5/9), DCR was 100% (9/9), however, ORR and DCR in patients who didn’t occurred acne-like rash within first 3 weeks were 0 and 33.3% (1/3), the difference ORR between two group was insignificant (P = 0.091), however, DCR was significant different (P = 0.007). There no treatment-associated death and no cetuximab-associated discontinuation. The incidence of acne-like rash was 83.3% (10/12) and 75% (9/12) occurred within first 3 weeks, there were eight patients suffered side effects associated with chemotherapy. So we can draw a conclusion that the short-term outcome of cetuximab application in first line setting for patients with NSCLC were promising since the higher ORR and DCR, especially those occurred acne-like rash within the first 3 weeks, and the addition of cetuximab in this population was safe.

Keywords

CetuximabNon-small cell lung cancerEfficacySafetyFirst lineChemotherapy

Abbreviations

NSCLC

Non-small cell lung cancer

CR

Complete response

PR

Partial response

SD

Stable disease

PD

Progression disease

ORR

Overall response rate

DCR

Disease control rate

TTP

Time to progression

OS

Overall survival

EGFR

Epidermal growth factor receptor

TKIs

Tyrosine kinase inhibitors

FLEX

First-line treatment for patients with EGFR-EXpressing advanced NSCLC

ASCO

American Society of Clinical Oncology

NCCN

National Comprehensive Cancer Network

WCLC

World Conference on Lung Cancer

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Liang-Ping Xia
    • 1
    • 2
  • Hui-Juan Qiu
    • 1
    • 2
  • Xu-Xian Chen
    • 1
    • 2
  • Pi-Li Hu
    • 1
    • 2
  • Gui-Fang Guo
    • 1
    • 2
  • Fang Wang
    • 1
    • 2
  • Fei-Fei Zhou
    • 3
  • Wen-Zhuo He
    • 1
    • 2
  • Bei Zhang
    • 1
    • 2
  • Li Zhang
    • 1
    • 4
  1. 1.State Key Laboratory of Oncology in South ChinaGuangzhouPeople’s Republic of China
  2. 2.VIP Region, Sun Yat-sen University Cancer CenterGuangzhouPeople’s Republic of China
  3. 3.Tumor Center, The Foshan First People’s HospitalFoshanPeople’s Republic of China
  4. 4.Department of Medical OncologySun Yat-sen University Cancer CenterGuangzhouPeople’s Republic of China